FCF Payout Ratio: 4.21%
Is the FCF payout ratio high or low?
The FCF payout ratio of 4.21% is 29% above its 3-year average of 3.26%, near the high end of its 3-year range (0.82%–4.43%).
1.18% above its 12-month average of 4.16%.
GEHC FCF Payout Ratio
Rolling trailing-12-month FCF payout ratio sampled each quarter; raw quarterly payout is intentionally not charted.
GEHC Average FCF Payout Ratio Chart
GEHC Current vs Average FCF Payout Ratio Chart
GEHC FCF Payout Ratio Metrics
FCF PAYOUT RATIO
4.21%
FCF PAYOUT RATIO AVG TTM
4.16%
FCF PAYOUT RATIO AVG 3Y
3.48%
FCF PAYOUT RATIO AVG 5Y
N/A
FCF PAYOUT RATIO AVG 10Y
N/A
FCF PAYOUT RATIO AVG 15Y
N/A
FCF PAYOUT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+1.18%
CURRENT VS 3Y AVG
+21.03%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Payout Ratio Comparison
FCF Payout Ratio TTM
4.2%
Earnings Payout Ratio
3.1%
Dividend Yield
0.21%
FCF Yield
5.06%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $1.51B | $64.00M | 4.2% |
| 2024 | $1.55B | $55.00M | 3.5% |
| 2023 | $1.71B | $41.00M | 2.4% |
| 2022 | $1.80B | $0 | 0.0% |
| 2021 | $1.36B | $0 | 0.0% |
| 2020 | $1.43B | $0 | 0.0% |
| 2019 | $1.66B | $0 | 0.0% |
Formula: FCF Payout Ratio TTM = trailing 4Q dividends paid / trailing 4Q free cash flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures trailing dividends paid as a percentage of trailing free cash flow. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
FCF Payout Ratio FAQ
- What is the FCF payout ratio for GE HealthCare Technologies Inc. (GEHC)?
- The FCF payout ratio for GEHC stock is 4.21%.
- Is GE HealthCare Technologies Inc.'s FCF payout ratio high or low?
- The FCF payout ratio of 4.21% is 29% above its 3-year average of 3.26%, near the high end of its 3-year range (0.82%–4.43%).
- What is the TTM average FCF payout ratio for GE HealthCare Technologies Inc. (GEHC)?
- The TTM average FCF payout ratio for GEHC stock is 4.16%.
- What is the 3Y average FCF payout ratio for GE HealthCare Technologies Inc. (GEHC)?
- The 3Y average FCF payout ratio for GEHC stock is 3.48%.
GEHC FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2026-03-31 | 4.21% |
| 2025-12-31 | 4.25% |
| 2025-09-30 | 4.43% |
| 2025-06-30 | 3.77% |
| 2025-03-31 | 4.15% |
| 2024-12-31 | 3.55% |
| 2024-09-30 | 3.19% |
| 2024-06-30 | 3.40% |
| 2024-03-31 | 3.31% |
| 2023-12-31 | 2.39% |
| 2023-09-30 | 1.63% |
| 2023-06-30 | 0.82% |
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini